Evogene Ltd. [NASDAQ: EVGN] traded at a high on 02/04/21, posting a 16.36 gain after which it closed the day’ session at $7.68. The company report on January 21, 2021 that Biomica Announces Participation at the Crohn’s & Colitis Congress® January 21-24, 2021 (Virtual Conference).
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), announced it will be featured as a presenting company at the Crohn’s & Colitis Congress® to be held from January 21-24, 2021.
Prof. Yehuda Ringel, CSO of Biomica, will present “BMC322 – A rationally-designed live bacterial consortium based on microbiome functional genomic analysis for treatment of IBD” on Saturday 23rd January, 2021 at 2PM (EST).
The results of the trading session contributed to over 3784553 shares changing hands. Over the past one week, the price volatility of Evogene Ltd. stands at 10.43% while the volatility over the past one month is 11.75%.
The market cap for EVGN stock reached $280.25 million, with 36.49 million shares outstanding and 28.82 million shares in the current float. Compared to the average trading volume of 1.72M shares, EVGN reached a trading volume of 3784553 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Evogene Ltd. [EVGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EVGN shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EVGN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Evogene Ltd. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 01, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on December 16, 2013, representing the official price target for Evogene Ltd. stock.
The Average True Range (ATR) for Evogene Ltd. is set at 0.72, with the Price to Sales ratio for EVGN stock in the period of the last 12 months amounting to 348.14. The Price to Book ratio for the last quarter was 5.41.
How has EVGN stock performed recently?
Evogene Ltd. [EVGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.94. With this latest performance, EVGN shares gained by 55.78% in over the last four-week period, additionally plugging by 550.85% over the last 6 months – not to mention a rise of 408.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVGN stock in for the last two-week period is set at 71.65, with the RSI for the last a single of trading hit 75.64, and the three-weeks RSI is set at 69.10 for Evogene Ltd. [EVGN]. The present Moving Average for the last 50 days of trading for this stock 4.86, while it was recorded at 6.69 for the last single week of trading, and 2.65 for the last 200 days.
Evogene Ltd. [EVGN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Evogene Ltd. [EVGN] shares currently have an operating margin of -3019.92 and a Gross Margin at -312.08. Evogene Ltd.’s Net Margin is presently recorded at -2405.31.
Return on Total Capital for EVGN is now -39.89, given the latest momentum, and Return on Invested Capital for the company is -35.13. Return on Equity for this stock declined to -35.83, with Return on Assets sitting at -27.71. When it comes to the capital structure of this company, Evogene Ltd. [EVGN] has a Total Debt to Total Equity ratio set at 5.92. Additionally, EVGN Total Debt to Total Capital is recorded at 5.59, with Total Debt to Total Assets ending up at 4.16. Long-Term Debt to Equity for the company is recorded at 4.14, with the Long-Term Debt to Total Capital now at 3.91.
Reflecting on the efficiency of the workforce at the company, Evogene Ltd. [EVGN] managed to generate an average of -$451,281 per employee. Receivables Turnover for the company is 0.77 with a Total Asset Turnover recorded at a value of 0.01.
Insider trade positions for Evogene Ltd. [EVGN]
There are presently around $65 million, or 23.92% of EVGN stock, in the hands of institutional investors. The top three institutional holders of EVGN stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 4,618,845, which is approximately 1068.615% of the company’s market cap and around 18.12% of the total institutional ownership; WADDELL & REED FINANCIAL INC, holding 2,757,223 shares of the stock with an approximate value of $21.18 million in EVGN stocks shares; and SENVEST MANAGEMENT, LLC, currently with $4.74 million in EVGN stock with ownership of nearly 29.901% of the company’s market capitalization.
Positions in Evogene Ltd. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 16 institutional holders increased their position in Evogene Ltd. [NASDAQ:EVGN] by around 4,607,199 shares. Additionally, 12 investors decreased positions by around 2,341,482 shares, while 1 investors held positions by with 1,527,482 shares. The mentioned changes placed institutional holdings at 8,476,163 shares, according to the latest SEC report filing. EVGN stock had 11 new institutional investments in for a total of 160,841 shares, while 8 institutional investors sold positions of 1,865,377 shares during the same period.